Abstract
Background
Antipsychotics are commonly prescribed in high doses in combination with multiple psychotropic drugs. This study focused on the high‐dose antipsychotic prescriptions in patients with schizophrenia, while aiming to identify their associations with patients’ characteristics and concurrent psychotropic prescriptions.
Methods
This cross‐sectional study used claims data from a prefecture in Japan, between October 2014 and March 2015, to investigate antipsychotic prescriptions in adult outpatients with schizophrenia. The objective variable was the presence/absence of a high‐dose prescription. The explanatory variables included sex, age (category), presence of comorbid conditions, and the use of psychiatrist's therapy.
Results
After exclusion, a total of 13 471 patients with schizophrenia were analyzed. The frequency of high‐dose prescriptions was higher in men, with chlorpromazine‐equivalent values highest in the age ranges of 45‐54 and 35‐44 years for men and women, respectively. Patients aged below 65 years with cerebrovascular diseases showed a decrease in high‐dose prescriptions. There was a high frequency of polypharmacy psychotropic drug use in combination with a high‐dose antipsychotic prescription in patients aged below 65 years.
Conclusion
High‐dose antipsychotics are often used in combination with several psychotropic agents in patients with schizophrenia. Our findings emphasize the need to evaluate the prescribing behavior of physicians to avoid high‐dose antipsychotic prescriptions for improved patient care.
Keywords: antidepressive agents, antipsychotic agents, hypnotics and sedatives, polypharmacy, schizophrenia
This study aimed to identify the association between concurrent psychotropic prescriptions and high‐dose antipsychotic prescriptions in patients with schizophrenia in Japan. In this study, high‐dose antipsychotics were often used in combination with several psychotropic agents in patients with schizophrenia. Our findings emphasize the need to evaluate the prescribing behavior of physicians to avoid high‐dose antipsychotic prescriptions for improved patient care.
1. INTRODUCTION
Antipsychotics are psychotropic drugs primarily used to treat schizophrenia and other psychotic disorders. In clinical practice, for treating schizophrenia, antipsychotics are typically prescribed in combination with mood stabilizers, antidepressants, and anxiolytics/hypnotics. 1 , 2 Anti‐Parkinson's agents are often included in multiple drug regimens (polypharmacy), and prescribed for both the prevention and treatment of adverse reactions, such as extrapyramidal symptoms (EPS). However, a study reported that side effects including disorientation and hallucinations might occur. 3
Patients with schizophrenia are often treated with second‐generation antipsychotics, which often carry the risk of adverse reactions, such as EPS, metabolic syndrome, endocrine disorders, cardiovascular disorders, and osteoporosis. 4 , 5 , 6 Moreover, high‐dose antipsychotic polypharmacy (APP) is reportedly associated with depressive disorders and even increased mortality rates. 7 , 8 In Japan, prescriptions of antipsychotics for treating schizophrenia mainly involve high‐dose APP, alongside concurrent medications. 9 Although APP use in Japan is widespread compared with that in other East Asian countries, 10 there has been a slight decrease over the years, owing to the adoption of second‐generation antipsychotic monotherapy. 11 , 12 , 13 Previous studies have chronicled the factors affecting antipsychotic prescription patterns and prevalence of polypharmacy in patients with schizophrenia. 14 , 15 However, studies examining the underlying factors associated with high‐dose APP and co‐prescriptions of other psychotropic medications in Japan since the growing use of second‐generation monotherapy are lacking.
Although it is well established that antipsychotics have adverse reactions, the frequency of high‐dose prescriptions has still not substantially decreased. 16 This is concerning, considering that the number of outpatients with schizophrenia is increasing. 17 , 18 , 19 To prevent the use of high‐dose prescriptions, we must first understand the factors that have contributed to the current paradigm of high‐dose prescriptions. Hence, it is pertinent to examine the factors in community‐dwelling outpatients. This study focused on the high‐dose antipsychotic prescriptions in outpatients with schizophrenia during their maintenance period using claims data from a single prefecture, while aiming to identify their associations between patients’ characteristics and concurrent psychotropic prescriptions (antidepressants, anxiolytics/hypnotics, mood stabilizers, and anti‐Parkinson's agents).
2. METHODS
2.1. Study design and participants
We conducted a cross‐sectional study to evaluate adult outpatients with schizophrenia treated with antipsychotics.
2.2. Data source
Claims data from both the National Health Insurance (Japan) (https://www.mhlw.go.jp/english/wp/wp‐hw3/dl/2‐001.pdf) and the Long Life Medical Care System (Japanese medical care system for the elderly adults aged 75 years or older), from a single prefecture between October 2014 and March 2015, were used for analysis. The data set was anonymized. Clinical data, including age at the start of the study (study start month – birth month), sex, coexisting diagnosis (diagnosis record), prescribed medicines (medicinal product codes), prescription days, dosages, and medical services were extracted. Previously published documents were used to define each psychotropic group. 20 We defined the following five drugs as mood stabilizers: sodium valproate, lithium carbonate, lamotrigine, carbamazepine, and topiramate. 21 Some antipsychotics, such as chlorpromazine and sulpiride, have multiple indications and were regarded as antipsychotics. The long‐acting injectable medications that were approved in Japan at the time of data collection were as follows: haloperidol decanoate, fluphenazine decanoate, risperidone, and paliperidone palmitate. 22 , 23
2.3. Study population
We included a total of 22 100 patients aged 18 years and older with schizophrenia, as the registered diagnosis (ICD‐10: F20). Patients whose main diagnosis was mood disorder (ICD‐10: F30.x‐39), dementia (ICD‐10: F00.x‐F07.x, F09), Alzheimer's disease (ICD‐10: G30.x), or epilepsy (ICD‐10: G40.x); patients who were prescribed anti‐dementia drugs and medications for peripheral symptoms of dementia; and patients whose prescription data did not exist for long periods of time due to a change in residence or medical institution were excluded. Additionally, patients with a short prescription duration (<28 days) were also excluded, since it was presumed that their prescriptions were constantly subject to change.
2.4. Drug utilization measures
The chlorpromazine‐equivalent value (CPZ equivalent) per patient was used to calculate the daily antipsychotic dose per patient based on the chlorpromazine dose equivalents for antipsychotics. 24 If a patient had prescription data of multiple months, we used the mean value of CPZ equivalents calculated monthly. 25
2.5. Statistical analyses
The objective variable was the presence or absence of a high‐dose antipsychotic prescription (binary data). Explanatory variables included sex, age (category), presence or absence of comorbidities, psychotropic drugs (antidepressants, anxiolytics/hypnotics, mood stabilizers, and anti‐Parkinson's agents) prescribed concurrently, and psychiatrist's therapy. Psychiatrist's therapy is a form of medical fee remuneration obtained when a doctor in charge of psychiatry continues to give instructions or advice under a certain treatment plan. A chi‐square test was conducted for the CPZ equivalent values, the frequency of high‐dose prescriptions and each explanatory variable, and those with a CPZ equivalent above 1000 mg/day of antipsychotics, which is considered as a high dose. 26 , 27
Finally, multiple logistic regression analysis was conducted separately for patients aged 18‐64 years (designated as adults) and for those aged 65 years and older (designated as older adults). The area under curve (C‐index) was calculated. A threshold of P < .05 was considered significant.
All analyses were performed using IBM SPSS Statistics for Windows, version 23.0. (IBM Corp.).
2.6. Ethical considerations
This study used anonymized data from an electronic data set; thus, it was not considered necessary to obtain consent from patients based on existing guidelines. 28 This study was approved by the Ethics Committee of the Kyoto University Graduate School of Medicine, Japan (R0438).
3. RESULTS
After exclusion, a total of 13 471 patients with schizophrenia qualified for the study, and the pertinent data were analyzed (Figure 1).
Figure 1.
Flow chart of the study participants
3.1. Prescribing characteristics
In Table 1, the frequency distribution of the CPZ equivalent was disaggregated by age and patient comedications. The mean and median CPZ equivalents were 368.3 mg/day and 200 mg/day, respectively. A total of 2945 (21.9%) patients received ≥600 mg/day, which is the set medical dosage guideline 29 , 30 for patients with schizophrenia in the maintenance period. Meanwhile, 1139 (8.5%) patients received 1000 mg/day (high‐dose prescriptions). The effective dose of antipsychotics for schizophrenia was assumed to be equal to the CPZ equivalent of 100 mg/day. 30 , 31 Moreover, 3599 (26.7%) patients received less than 100 mg/day.
Table 1.
Chlorpromazine‐equivalent values by age and co‐prescription
| 0‐100 mg | 100‐200 mg | 200‐300 mg | 300‐600 mg | 600‐1000 mg | ≥1000 mg | Total | |
|---|---|---|---|---|---|---|---|
| Age (y), n (%) | 3608 | 2526 | 1679 | 2713 | 1806 | 1139 | |
| 18‐34 | 273 (19.5) | 240 (17.1) | 198 (14.1) | 324 (23.1) | 229 (16.3) | 139 (9.9) | 1403 |
| 35‐44 | 372 (13.3) | 404 (14.4) | 353 (12.6) | 741 (26.4) | 549 (19.6) | 385 (13.7) | 2804 |
| 45‐54 | 314 (13.9) | 346 (15.3) | 264 (11.6) | 561 (24.7) | 436 (19.2) | 346 (15.3) | 2267 |
| 55‐64 | 356 (18.2) | 347 (17.7) | 281 (14.3) | 479 (24.5) | 324 (16.5) | 172 (8.8) | 1959 |
| 65‐74 | 677 (30.0) | 497 (22.1) | 347 (15.4) | 431 (19.1) | 217 (9.6) | 84 (3.7) | 2253 |
| ≥75 | 1616 (58.0) | 692 (24.8) | 236 (8.5) | 177 (6.4) | 51 (1.8) | 13 (0.5) | 2785 |
| Comedications, n (%) | |||||||
| Anxiolytics/hypnotics | 1918 (24.6) | 1399 (17.9) | 910 (11.7) | 1573 (20.1) | 1172 (15.0) | 837 (10.7) | 7809 |
| Antidepressants | 881 (33.4) | 564 (21.4) | 320 (12.1) | 446 (16.9) | 277 (10.5) | 146 (5.5) | 2634 |
| Mood stabilizers | 657 (22.0) | 483 (16.2) | 333 (11.2) | 597 (20.0) | 504 (16.9) | 405 (13.6) | 2979 |
| Anti‐Parkinson's | 587 (13.7) | 581 (13.5) | 502 (11.7) | 1062 (24.7) | 861 (20.0) | 706 (16.4) | 4299 |
3.2. Relationship between each explanatory variable and CPZ equivalent
The characteristics of the patients classified by sex and age, presence or absence of comorbidities, presence or absence of each psychotropic prescription, CPZ equivalent, and percentage of high‐dose prescriptions are shown in Table 2. The percentage of high‐dose prescriptions was lower in patients with diabetes mellitus, cardiovascular, cerebrovascular, or kidney diseases than in those without any comorbidity. In this study, 7809 (58.0%) patients were prescribed with anxiolytics/hypnotics, 2634 (19.6%) were prescribed antidepressants, 2979 (22.1%) were prescribed mood stabilizers, and 4299 (31.9%) were prescribed anti‐Parkinson's agents. Among the patients prescribed a CPZ equivalent of 1000 mg/day or more (a high‐dose prescription), 837 (73.5%) were prescribed anxiolytics/hypnotics, 146 (12.8%) were prescribed antidepressants, 405 (35.6%) were prescribed mood stabilizers, and 706 (70.0%) were prescribed anti‐Parkinson's agents.
Table 2.
Demographic and clinical characteristics
|
n (%) n = 13 471 |
High‐dose prescription a , n (%) n = 1139 (8.5%) |
P‐value | |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 6047 (44.9) | 631 (10.4) | <.001 |
| Female | 7424 (55.1) | 508 (6.8) | |
| Age (y), n (%) | |||
| 18‐34 | 1403 (10.4) | 139 (9.9) | <.001 |
| 35‐44 | 2804 (20.8) | 385 (13.7) | |
| 45‐54 | 2267 (16.8) | 346 (15.3) | |
| 55‐64 | 1959 (14.5) | 172 (8.8) | |
| 65‐74 | 2253 (16.7) | 84 (3.7) | |
| ≥75 | 2785 (20.7) | 13 (0.5) | |
| Comorbidity, n (%) | |||
| Cardiovascular diseases | 2039 (15.1) | 67 (3.3) | <.001 |
| Cerebrovascular diseases | 2001 (14.9) | 35 (1.7) | <.001 |
| Liver dysfunction | 3152 (23.4) | 247 (7.8) | .154 |
| Diabetes mellitus | 549 (4.1) | 31 (5.6) | .016 |
| Kidney diseases | 334 (2.5) | 8 (2.4) | <.001 |
| No registered diseases | 7842 (58.2) | 812 (71.3) | <.001 |
| Comedications | |||
| Anxiolytics/hypnotics | 7809 (58.0) | 837 (10.7) | <.001 |
| Antidepressants | 2634 (19.6) | 146 (5.5) | <.001 |
| Mood stabilizers | 2979 (22.1) | 405 (13.6) | <.001 |
| Anti‐Parkinson's | 4299 (31.9) | 706 (16.4) | <.001 |
| Department, n (%) | |||
| Psychiatrist's therapy | 9792 (72.7) | 896 (9.2) | <.001 |
Chlorpromazine‐equivalent value ≥ 1000 mg.
3.3. Relationship between sex, age, and high‐dose prescriptions
The percentage of patients with high‐dose prescriptions was higher in men. CPZ equivalents were highest in the groups aged 45‐54 and 35‐44 years in both men and women, respectively (Table 3).
Table 3.
Sex/age classification and chlorpromazine‐equivalent value
| Age (y) | Sex | n | Mean (mg) | Median (mg) | 1,000 mg or more (n) | P‐value |
|---|---|---|---|---|---|---|
| 18‐34 | Male | 702 | 453.0 | 300.0 | 10.7% (75) | .330 |
| Female | 701 | 384.3 | 226.7 | 9.1% (64) | ||
| 35‐44 | Male | 1470 | 539.1 | 400.0 | 14.6% (214) | .181 |
| Female | 1334 | 478.0 | 323.9 | 12.8% (171) | ||
| 45‐54 | Male | 1238 | 569.5 | 400.0 | 17.9% (221) | <.001 |
| Female | 1029 | 473.2 | 300.0 | 12.2% (125) | ||
| 55‐64 | Male | 881 | 441.9 | 305.5 | 9.8% (86) | .165 |
| Female | 1078 | 378.8 | 240.0 | 8.0% (86) | ||
| 65‐74 | Male | 923 | 269.9 | 163.1 | 3.5% (32) | .585 |
| Female | 1330 | 275.9 | 170.7 | 3.9% (52) | ||
| ≥75 | Male | 833 | 116.5 | 75.8 | 0.4% (3) | .590 |
| Female | 1952 | 123.5 | 75.8 | 0.5% (10) |
3.4. Factors associated with high‐dose prescriptions
Owing to the observed differences in the number of high‐dose antipsychotic prescriptions by age, a stratified analysis of high‐dose prescription factors was conducted to compare patients aged below 65 years old with those aged over 65 years. A higher percentage of people aged 65 years and older was found in the low‐dose group with a CPZ equivalent of less than 100 mg/day (Table 1). A multiple logistic regression analysis was conducted. In this analysis, the patients with CPZ equivalents of less than 100 mg/day were excluded to rule out the possibility of including patients with mood disorders or dementia from the medical fee data.
The adjusted odds ratio (OR) of a high‐dose antipsychotic prescription was significantly higher in men aged 45‐49 years (1.50; P = .014). For both men and women aged 60‐64 years, the adjusted OR was lower (men: 0.54, P = .006; women: 0.51, P = .002). The adjusted OR for high‐dose prescriptions was lower (0.55, P = .007) in patients with cerebrovascular disease. The adjusted OR was significantly higher for patients using psychotropics in combination with high‐dose prescription (1.69 for anxiolytics/hypnotics and mood stabilizers, P < .001; 2.55 for anti‐Parkinson's agents). The adjusted OR for the high‐dose prescriptions was as low as 0.71 (95% CI: 0.60‐0.85) in patients who received psychiatrist's therapy (Table 4).
Table 4.
Factors associated with high‐dose antipsychotic prescriptions: multivariable analyses
| Odds ratio | 95% CI | P‐value | |
|---|---|---|---|
| Males, age (y) | |||
| 18‐34 | Ref. | ||
| 35‐39 | 1.23 | 0.87‐1.73 | .239 |
| 40‐44 | 1.12 | 0.81‐1.54 | .505 |
| 45‐49 | 1.50 | 1.08‐2.06 | .014 |
| 50‐54 | 1.40 | 0.99‐2.00 | .055 |
| 55‐59 | 1.05 | 0.71‐1.56 | .814 |
| 60‐64 | 0.54 | 0.34‐0.84 | .006 |
| Females, age (y) | |||
| 18‐34 | 0.89 | 0.62‐1.29 | .538 |
| 35‐39 | 1.13 | 0.79‐1.63 | .505 |
| 40‐44 | 1.11 | 0.80‐1.55 | .534 |
| 45‐49 | 0.98 | 0.68‐1.41 | .897 |
| 50‐54 | 1.03 | 0.71‐1.51 | .867 |
| 55‐59 | 0.95 | 0.64‐1.42 | .796 |
| 60‐64 | 0.51 | 0.34‐0.78 | .002 |
| Cardiovascular diseases | 0.95 | 0.69‐1.31 | .762 |
| Cerebrovascular diseases | 0.55 | 0.36‐0.85 | .007 |
| Liver dysfunction | 0.90 | 0.76‐1.06 | .195 |
| Diabetes mellitus | 0.85 | 0.54‐1.33 | .468 |
| Kidney diseases | 1.03 | 0.44‐2.41 | .938 |
| Anxiolytics/hypnotics | 1.69 | 1.45‐1.97 | <.001 |
| Antidepressants | 0.63 | 0.52‐0.77 | <.001 |
| Mood stabilizers | 1.69 | 1.46‐1.95 | <.001 |
| Anti‐Parkinson's | 2.55 | 2.22‐2.94 | <.001 |
| Psychiatrist's therapy | 0.71 | 0.60‐0.85 | <.001 |
AUC, area under the curve; CI, confidence interval.
Odds ratios are shown with their 95% Cls.
AUC = 0.701.
In the logistic regression analysis for the patients aged 65 years or over, the adjusted OR for women aged 80 years and older was significantly lower (0.15, P = .003). The adjusted OR was significantly higher for psychotropics used in combination with a high‐dose prescription (1.69, P = .024 for anxiolytics/hypnotics and 3.31, P < .001 for anti‐Parkinson's agents); however, the adjusted OR was significantly lower at 0.45 (95% CI: 0.20‐1.00, P = .048) for antidepressants (Table 5).
Table 5.
Factors associated with high‐dose antipsychotic prescriptions in older indivisuals: multivariable analyses
| Odds ratio | 95% CI | P‐value | |
|---|---|---|---|
| Males, age (y) | |||
| 65‐69 | Ref. | ||
| 70‐74 | 0.64 | 0.29‐1.42 | .268 |
| 75‐79 | 0.15 | 0.02‐1.16 | .069 |
| ≥80 | 0.39 | 0.087‐1.76 | .220 |
| Females, age (y) | |||
| 65‐69 | 1.04 | 0.59‐1.83 | .893 |
| 70‐74 | 0.90 | 0.48‐1.70 | .750 |
| 75‐79 | 0.46 | 0.19‐1.09 | .078 |
| ≥80 | 0.15 | 0.044‐0.53 | .003 |
| Cardiovascular diseases | 1.06 | 0.60‐1.88 | .835 |
| Cerebrovascular diseases | 0.52 | 0.26‐1.04 | .063 |
| Liver dysfunction | 1.08 | 0.66‐1.76 | .756 |
| Diabetes mellitus | 0.97 | 0.43‐2.19 | .942 |
| Kidney diseases | 0.36 | 0.049‐2.70 | .323 |
| Anxiolytics/hypnotics | 1.69 | 1.07‐2.66 | .024 |
| Antidepressants | 0.45 | 0.20‐1.00 | .048 |
| Mood stabilizers | 1.20 | 0.68‐2.10 | .535 |
| Anti‐Parkinson's | 3.31 | 2.12‐5.18 | <.001 |
| Psychiatrist's therapy | 1.02 | 0.61‐1.71 | .930 |
AUC, area under the curve; CI, confidence interval.
Odds ratios are shown with their 95% Cls.
AUC = 0.781.
4. DISCUSSION
This study focused on the high‐dose antipsychotic prescriptions in outpatients with schizophrenia while aiming to identify their associations between patients’ characteristics and concurrent psychotropic prescriptions.
4.1. Mean Dose in CPZ equivalent
The mean value of CPZ equivalent obtained in this study (368.3 mg/day) was higher than the one reported in a large‐scale survey of antipsychotic drugs in Japan (239 g/day) that targeted outpatient data (1272 people) from health insurance associatiations. 32 In the previous study, participants were workers aged 0‐74 years and their families, and the medical fee information was extracted from approximately 330,000 beneficiaries from multiple health insurance associations. The age distributions in the present and the previous study (which included diseases other than schizophrenia) differed. These differences in the target populations may have contributed to the discrepancy in the mean dose.
4.2. Relationship Between Sex, Age, and High‐Dose Prescriptions
High‐dose prescriptions by age were higher in men aged 45‐49 years than in younger men (adjusted OR = 1.23). The adjusted OR was 0.54 in patients aged 60‐64 years. A previous study revealed that middle‐aged people were also prescribed higher doses, whereas older people were prescribed lower doses. 33
While a previous study suggested that there was no difference between high‐dose prescriptions in men and women, 27 our data revealed that high‐dose prescriptions were significantly higher in men (10.4%) than in women (6.8%). This might be due to the differences in the time frame of the current study compared with that of the previous study. However, as our study population was not necessarily a representative sample of all Japanese individuals with schizophrenia, there may be inherent population‐specific differences related to the high‐dose antipsychotic prescriptions between the two genders.
With regard to sex differences by age, only men aged 45‐54 years had a significantly higher percentage of high‐dose prescriptions than women of the same age group.
4.3. Relationship between high‐dose antipsychotics and concurrent psychotropics
Patients aged less than 65 years were more likely to be prescribed mood stabilizers and anxiolytics/hypnotics with large doses of antipsychotics, which was consistent with the findings of the previous studies. 14 , 34 The reason for the additional use of mood stabilizers lacks persuasive evidence. 35 However, mood stabilizers are typically prescribed in combination with antipsychotics for the purpose of sedation to treat symptoms such as hostility and aggression. In our study, antipsychotics were frequently used in combination with anxiolytics/hypnotics. This finding suggests that anxiolytics/hypnotics are often prescribed as treatment for insomnia, depression, and anxiety, which seems to be increasing in patients with schizophrenia. 36
Prescriptions of antidepressants were low in all age groups. The reasons for the negative symptoms, such as amotivation, blunted affect, and asociality experienced by patients with schizophrenia in the chronic maintenance phase are unknown. Furthermore, the effectiveness of antidepressants in comorbid major depressive episodes remains unclear. 1 Although the use of a combination of antipsychotics and antidepressants to treat negative symptoms and comorbid major depressive episodes has been reported, 34 Asian clinicians do not prescribe antidepressants as frequently as those in other countries. 14
Patients who were prescribed large amounts of antipsychotics had many concomitant prescriptions of anti‐Parkinson's agents. This result was consistent with those of previous studies 14 , 37 and suggests that anti‐Parkinson's agents are often used in combination with prophylactics to treat side effects such as EPS.
4.4. Relationship between psychiatrist's therapy and high‐dose prescriptions
The adjusted OR for the rate of high‐dose prescriptions was as low as 0.71 (95% CI: 0.60‐0.85) in patients aged <65 years who received psychiatrist's therapy. In addition, the medical fee can be claimed only by the mental health institution, except in special cases (such as a psychiatrist consulting in a private hospital). This nonpharmacologic intervention may be related to the reduced rate of high‐dose prescriptions. The effects of psychiatrist's therapy on reducing antipsychotic high‐dose prescriptions suggest the need for more holistic treatment plan for schizophrenia. In the future, studies assessing the diversity in interventions and prescription of antipsychotic drugs by physicians and institution‐wide practices could help improve patient care.
4.5. Limitations
This study has several limitations. First, this study employed a cross‐sectional design; hence, changes in prescriptions (add‐ons and discontinued agents) could not be assessed. Second, the proportions of middle‐aged and elderly people among National Health Insurance beneficiaries are higher than those of Japanese population; thus, the average age may be skewed and affect the results. Therefore, in this study, age classification was introduced as a variable within our logistic regression analysis to assess the factors related to high‐dose prescriptions. Third, during the maintenance period, there are often changes in drug prescriptions within a short span of time. Thus, we excluded patients who were prescribed drugs for less than 28 days.
In Japan, only a limited number of antipsychotics are approved as medications for delirium and various mood disorders. Thus, for such disorders, antipsychotics are sometimes prescribed with the diagnosis of “schizophrenia” to claim fees. 38 To account for this, we excluded patients who has main diagnosis codes of mood disorders, dementia, Alzheimer's disease, or epilepsy as well as schizophrenia from the analysis.
As we excluded patients who were prescribed drugs for less than 28 days, we likely excluded patients with acute delirium who were treated with antipsychotics, although we cannot rule out the possibility that additional non‐schizophrenia use of antipsychotics was included.
The present study evaluated a large‐scale claims data set. Our results showed that anxiolytics/hypnotics and anti‐Parkinson's agents were often used in combination in patients with schizophrenia for whom antipsychotics were prescribed at high dosage. Antidepressants were used to a lesser extent in combination with high‐dose antipsychotics in these patients.
Our study emphasizes the immediate need in Japan to evaluate the prescription tendencies of physicians and institutions to help avoid high‐dose antipsychotic prescriptions to improve patient care. It is important for doctors and medical institutions prescribing high‐dose drugs to be reviewed the contents of and prescription periods for combination treatment.
CONFLICT OF INTEREST
The authors declare that they had no conflict of interest.
AUTHOR CONTRIBUTIONS
Dr Takahashi contributed to the design of the study, data extraction, statistical analysis, and writing of the manuscript. Dr Otsubo contributed to design of the study, data extraction, and writing of the manuscript. Dr Kunisawa contributed to the data extraction and statistical analysis. Dr Sasaki contributed to the writing of the manuscript. Dr Imanaka contributed to the design of the study, writing of the manuscript, and management of the overall study process. All authors approved the final version of the manuscript.
ETHICAL APPROVAL
The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution, and it conforms to the provisions of the Declaration of Helsinki (Committee of Kyoto University Graduate School of Medicine, Japan, approval no. R0438).
DATA AVAILABLE STATEMENT
The data that support the findings of this study are proprietary data of the prefectural government and therefore are not publicly available. However, the data might be available from the prefectural government upon reasonable request.
ACKNOWLEDGMENTS
This study was supported by Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (H27‐iryo‐ippan‐001; http://www.mhlw.go.jp), and a Grant‐in‐Aid for Scientific Research from the Japan Society for the Promotion of Science ([A]16H02634; https://www.jsps.go.jp/j‐grantsinaid/). Y. Imanaka received these funds. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Editorial support in the form of English writing was provided by Editage (www.editage.com), a brand of Cactus Communications Pvt.
Takahashi T, Otsubo T, Kunisawa S, Noriko S, Imanaka Y. Factors associated with high‐dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture. Neuropsychopharmacol Rep. 2020;40:224–231. 10.1002/npr2.12109
REFERENCES
- 1. Terevnikov V, Joffe G, Stenberg JH. Randomized controlled trials of add‐on antidepressants in schizophrenia. Int J Neuropsychopharmacol. 2015;18(9):pyv049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476–83. [DOI] [PubMed] [Google Scholar]
- 3. Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68(1):37–49. [DOI] [PubMed] [Google Scholar]
- 4. Yogaratnam J, Biswas N, Vadivel R, Jacob R. Metabolic complications of schizophrenia and antipsychotic medications‐an updated review. East Asian Arch Psychiatry. 2013;23(1):21–8. [PubMed] [Google Scholar]
- 5. Scigliano G, Ronchetti G. Antipsychotic‐induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M et al The impact of prolactin‐raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147(2–3):383–6. [DOI] [PubMed] [Google Scholar]
- 7. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17(7):1083–93. [DOI] [PubMed] [Google Scholar]
- 8. Joukamaa M, HeliÖvaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188(2):122–7. [DOI] [PubMed] [Google Scholar]
- 9. Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU. Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and rationales. Psychiatry Res. 2013;209(3):406–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Sim K, Su A, Fujii S, Yang S‐Y, Chong M‐Y, Ungvari GS et al Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 2004;58(2):178–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Kochi K, Sato I, Nishiyama C, Tanaka‐Mizuno S, Doi Y, Arai M et al Trends in antipsychotic prescriptions for Japanese outpatients during 2006–2012: a descriptive epidemiological study. Pharmacoepidemiol Drug Saf. 2017;26(6):642–56. [DOI] [PubMed] [Google Scholar]
- 12. Okumura Y, Togo T, Fujita J. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010. Int Psychogeriatr. 2015;27(3):407–15. [DOI] [PubMed] [Google Scholar]
- 13. Yoshio T. The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group. Seishin Shinkeigaku Zasshi. 2012;114(6):690–5. [PubMed] [Google Scholar]
- 14. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta‐regression of global and regional trends from the 1970s to 2009. Schizophr Res. 1970s;138(1):18–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr Res. 2010;119(1–3):145–52. [DOI] [PubMed] [Google Scholar]
- 16. Xiang Y‐T, Li Y, Correll CU, Ungvari GS, Chiu HFK, Lai KYC et al Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001–2009). Int J Geriatr Psychiatry. 2014;29(4):359–66. [DOI] [PubMed] [Google Scholar]
- 17. Ministry of Health, Labour and Welfare of Japan [internet] A vision for reforming mental health and welfare services 2004 [Cited Feb 6 2018] Available from http://www.mhlw.go.jp/topics/2004/09/dl/tp0902‐1a.pdf
- 18. Ministry of Health, Labour and Welfare of Japan [internet] Further reform of health and welfare services for persons with mental illness 2009 [Cited Feb 6 2018]. Available from http://www.mhlw.go.jp/shingi/2009/09/dl/s0924‐2a.pdf
- 19. Ministry of Health, Labour and Welfare of Japan [internet] Summary of patient survey 2011. 2011. [Cited Feb 6 2018]. Available from http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/dl/toukei.pdf
- 20. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440–7. [DOI] [PubMed] [Google Scholar]
- 21. Young LT. What exactly is a mood stabilizer? J Psychiatry Neurosci. 2004;29(2):87–8. [PMC free article] [PubMed] [Google Scholar]
- 22. Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XX: dose equivalence of injectable antipsychotics. J Clin Psychopharmacol. 2007;10(2):373–7. [Google Scholar]
- 23. Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXII: Dose equivalence of depot antipsychotics III: risperidon long‐acting injection. J Clin Psychopharmacol. 2010;13:1349–4353. [Google Scholar]
- 24. Inagaki A, Inada T. Dose equivalence of psychotropic drugs, Part XXI: Dose equivalence of novel antipsychotics: Blonanserin. J Clin Psychopharmacol. 2008;11:887–90. [Google Scholar]
- 25. DosReis S, Zito JM, Buchanan RW, Lehman AF. Antipsychotic dosing and concurrent psychotropic treatments for Medicaid‐insured individuals with schizophrenia. Schizophr Bull. 2002;28(4):607–17. [DOI] [PubMed] [Google Scholar]
- 26. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. Br J Psychiatry. 2005;187(3):243–7. [DOI] [PubMed] [Google Scholar]
- 27. Sim K, Su HC, Fujii S, Yang S‐Y, Chong M‐Y, Ungvari G et al High‐dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol. 2009;67(1):110–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare of Japan [internet] Ethical guidelines for epidemiological research June 2002 [Cited Mar 7 2017]. Available from https://www.mhlw.go.jp/seikakunitsuite/bunya/hokabunya/kenkyuujigyou/i‐kenkyu/dl/02‐02.pdf
- 29. Xiang Y‐T, Dickerson F, Kreyenbuhl J, Ungvari GS, Wang C‐Y, Si T‐M et al Prescribing patterns of low doses of antipsychotic medications in older Asian patients with schizophrenia, 2001–2009. Int Psychogeriatr. 2012;24(6):1002–8. [DOI] [PubMed] [Google Scholar]
- 30. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines. London: CRC Press; 2009. [Google Scholar]
- 31. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose‐years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Ministry of Health, Labour and Welfare of Japan [internet] A study on actual condition on psychotropic drug prescription using medical fee compensation data 2010 [Cited Jun 13 2018]. Available from http://www.ncnp.go.jp/tmc/pdf/22_report02.pdf
- 33. Okumura Y, Noda H, Ito H. Prescription pattern of antipsychotics in schizophrenia patients throughout Japan: Utilization of National Database. Jpn J Clin Psychopharmacol. 2013;9:1201–5. [Google Scholar]
- 34. Armstrong KS, Temmingh H. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: findings from a cross‐sectional study in an upper‐middle‐income country. Rev Bras Psiquiatr. 2017;39(4):293–301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Zink M, Englisch S, Meyer‐Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010;23(2):103–11. [DOI] [PubMed] [Google Scholar]
- 36. Roh D, Chang JG, Kim CH, Cho HS, An SK, Jung YC. Antipsychotic polypharmacy and high‐dose prescription in schizophrenia: a 5‐year comparison. Aust N Z J Psychiatry. 2014;48(1):52–60. [DOI] [PubMed] [Google Scholar]
- 37. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. Increased risk of extrapyramidal side‐effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand. 2006;113(2):135–41. [DOI] [PubMed] [Google Scholar]
- 38. Ministry of Health, Labour and Welfare of Japan [internet] Psychotropic drug use guideline corresponding to BPSD (2nd edition) 2016 [Cited Jun 13 2018]. Available from http://www.mhlw.go.jp/file/06‐Seisakujouhou